Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Sagimet Biosciences Q3 2026 Results: Net Loss of $19.1M, Loss Widens

Sagimet Biosciences Inc. reported a significant increase in total assets to $282.1 million as of September 30, 2026, up from $116.5 million at the end of 2025, primarily driven by growth in cash and marketable securities. The company is advancing its lead drug candidate, denifanstat, through clinical trials for metabolic dysfunction-associated steatohepatitis (MASH) and other indications. Current liabilities also increased to $38.0 million, including a $27.5 million liability for proceeds received for equity not yet issued.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income-19.1-12.9
EPS (diluted, $ a share)$-0.31$-0.40

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: SGMT. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Sagimet Biosciences Inc.: key numbers

Share price
$10.13Close, Nov 16
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Sagimet Biosciences Inc.

All →
7:49 AM ET 8-K
Financial Results

Sagimet Biosciences Financial Results

Sagimet Biosciences reported third quarter 2026 financial results and provided a corporate update on its Phase 3 AURORA clinical trial for denifanstat in moderate to severe acne. The company highlighted a pro forma cash position of $356 million following a $115 million equity financing in October, which is expected to fund operations through mid-2029.

“Building on the positive Phase 3 results from our license partner Ascletis, we have initiated our pivotal U.S. AURORA Phase 3 clinical trial. With our October equity financing, we are well positioned to fund our programs through mid-2029, including the anticipated Phase 3 denifanstat data readout and the potential submission of an NDA.”

David Happel, Chief Executive Officer
7:16 AM ET 8-K
Investor Presentation

Sagimet Biosciences Investor Presentation

Sagimet Biosciences Inc. has updated its corporate investor presentation, which will be used by management in upcoming meetings with investors. The presentation, filed as Exhibit 99.1, provides an overview of the company's novel therapeutics targeting metabolic dysfunction, including its lead candidate denifanstat.

6:02 AM ET 8-K
Capital Raise

Sagimet Biosciences Capital Raise of $115M

Sagimet Biosciences Inc. entered into an underwriting agreement for a public offering of 8,750,010 shares of Series A common stock at $10.00 per share and 2,750,010 pre-funded warrants at $9.9999 per share. The company expects to receive net proceeds of approximately $107.5 million, which will be used to fund a Phase 3 clinical trial for denifanstat in acne and other clinical development programs.

Value
$115M
Counterparty
Leerink Partners LLC, TD Securities (USA) LLC and Guggenheim Securities, LLC
6:10 AM ET 8-K
Deal Termination

Sagimet Biosciences Deal Termination with Leerink Partners LLC

Sagimet Biosciences has suspended and terminated its at-the-market (ATM) offering prospectus supplement related to its Series A common stock. The company will not make any further sales under the sales agreement with Leerink Partners LLC until a new prospectus or registration statement is filed. The filing also included an updated investor presentation and clinical trial results for denifanstat in acne vulgaris.

Counterparty
Leerink Partners LLC

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.